What leon nanodrugs does

Leon Nanodrugs (leon-nanodrugs GmbH) is a Munich-based pharmatech company that develops and commercializes scalable nanoparticle manufacturing equipment built around its patented FR-JET® impingement mixing technology. The platform uses two high-velocity fluid jets colliding inside a variable-sized spherical core to produce highly turbulent, precisely controlled mixing, enabling nanoparticle formulations without the clogging and scalability constraints of conventional microfluidic mixers. Four tiered NANO® products — NANOscreen® (benchtop screening), NANOlab® (process development), NANOme® (GMP clinical trial manufacturing), and NANOus® (commercial-scale continuous GMP production) — span the full R&D-to-commercial journey on a single core technology, eliminating process re-engineering between scales and supporting lipid mixture concentrations above 50 mg/mL for advanced therapeutics.

The company sells, leases, and rents its equipment and offers collaborative formulation development and technology-transfer services to pharmaceutical and biotechnology companies developing RNA medicines, cancer vaccines, cell and gene therapies, and personalized nanoparticle therapeutics, as well as to contract development and manufacturing organizations (CDMOs). Pricing is quote-based across engagement models (demo, rent, lease, buy), and a non-exclusive global distribution and after-sales partnership with Harro Höfliger (announced February 2026) extends reach beyond a sub-50-employee direct sales organization. Revenue is undisclosed, but the capital equipment–plus-services mix and installed-base economics position the company at the early commercial-deployment stage.

Leon Nanodrugs is privately held, venture-backed through Series D funding (August 2024, led by LBBW Venture Capital) and an oversubscribed financing round (February 2026), with additional strategic capital from TVM Capital Life Science, Albany Private Equity Holdings, CD-Venture, Eckenstein-Geigy-Stiftung, and Evotec SE. The company underwent a comprehensive leadership refresh in 2025–2026, installing Dr. Wolfgang Hofmann (ex-Novartis, ex-Fresenius) as CEO, Dr. Blerina Shkodra (ex-CureVac) as CSO, and Dr. Matthias Schumacher as CTO, with Dr. Frank Muehlenbeck (LBBW VC) as Chairman of the Supervisory Board. Peer-reviewed validation of the FR-JET® technology was published in Pharmaceutics in January 2026, and a coordinated US market launch event is scheduled in Boston for July 2026.

Name

leon nanodrugs

Legal name

leon-nanodrugs GmbH

Website

https://leon-nanodrugs.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Munich-based Leon Nanodrugs develops and commercializes scalable nanoparticle manufacturing equipment built on its patented FR-JET® impingement mixing technology, serving pharmaceutical companies, biotech firms, and CDMOs developing RNA medicines, cancer vaccines, and cell and gene therapies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing Equipment

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Nanoparticle manufacturing systems
• Pharmaceutical manufacturing equipment
• Lipid nanoparticle production
• Drug delivery technology
• GMP manufacturing solutions

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Equipment Sales: Sale of nanoparticle manufacturing systems (NANOscreen®, NANOlab®, NANOme®, NANOus®). One-time capital equipment purchases with complete onboarding and service packages.
2. Equipment Leasing: Long-term lease arrangements with predictable costs, full service included, and option to purchase at end of lease term. Provides flexibility for customers while generating recurring revenue.
3. Equipment Rental: Short-term rental for trials, feasibility studies, or specific project phases. Flexible equipment access with full support available.
4. Formulation Development Services: Collaborative R&D partnerships, end-to-end formulation optimization with expert support, and technology transfer services. Process development and optimization for clients.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Leon Nanodrugs develops and commercializes proprietary FR-JET® impingement mixing technology for scalable nanoparticle manufacturing, selling four tiered capital equipment systems (NANOscreen®, NANOlab®, NANOme®, NANOus®) that enable pharmaceutical and biotech companies to manufacture lipid nanoparticles and other nanoencapsulated drug products from early-stage R&D through commercial GMP production. The company also offers collaborative formulation development services, on-site system testing, and flexible equipment rental and leasing arrangements powered by the same core FR-JET® technology.

Product overview

LEON Nanodrugs offers a platform-plus-modules architecture built on a single core technology: the patented FR-JET® impingement mixer. The product portfolio consists of four tiered NANO® systems designed for seamless scale-up from R&D to GMP manufacturing: NANOscreen® for rapid screening and formulation identification, NANOlab® for process development and non-GMP manufacturing, NANOme® for GMP clinical trial manufacturing, and NANOus® for large-scale commercial production. The platform enables pharmaceutical companies, biotech firms, and CDMOs to encapsulate active pharmaceutical ingredients, including genetic payloads, into nanoparticles for advanced drug delivery without requiring process redesign or re-development between scales.

Differentiator

Problem solved

Functional benefit

Brands

• FR-JET®: Patented impingement jet mixer technology for nanoparticle manufacturing
• NANOscreen®
• NANOlab®
• NANOme®
• NANOus®

Products and services

• NANOscreen®

Quantifiable outcome

• LNPs formulated at lipid mixture concentrations above 50 mg/mL (vs. industry standard)
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and strategic.

• Harro HöfligercoreChannel Partner/ Reseller/ Distributor · 19 February 2026Strategic collaboration for global distribution and after-sales service of LEON's nanoencapsulation equipment. Harro Höfliger becomes a non-exclusive global authorized commercialization and service partner. The partnership leverages Harro Höfliger's decades of GMP-compliant production expertise and international sales and service network to expand worldwide access to LEON's FR-JET® technology.
• Evotec SEstrategicStrategic or Co-development PartnerStrategic partnership to maximize effectiveness of clinical and commercial nano-medicine development. LEON and Evotec collaborate to further research in multiple health fields including cancer and infectious diseases.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Others

• Harro Höfliger: Harro Höfliger is LEON's strategic global distribution and after-sales service partner, also an established supplier of GMP manufacturing equipment for pharma packaging, assembly, and process technology. Comparable as a GMP equipment specialist serving pharma manufacturers globally.

Broad incumbents

• West Pharmaceutical Services: West is a major supplier of drug delivery and containment components for injectable therapeutics, including devices used in nanoparticle drug delivery. Serves overlapping pharma/biotech customers and operates in the advanced drug delivery ecosystem relevant to LEON's nanoparticle manufacturing buyers.
• Evonik Industries: Evonik supplies specialty lipids and excipients (e.g., for LNPs) and has invested in pharmaceutical formulation/CDMO capabilities. Adjacent to LEON as a materials supplier and formulation services competitor in the same advanced drug delivery value chain.
• Thermo Fisher Scientific: Thermo Fisher offers a broad portfolio of pharmaceutical manufacturing equipment, drug substance services, and laboratory instruments that overlap with LEON's nanoparticle manufacturing platform in pharma/biotech customer accounts.
• Catalent (Novo Holdings): Catalent is a major global CDMO with significant LNP and nanoparticle drug product capabilities, including its role in COVID-19 vaccine manufacturing. Competes for the same advanced therapeutics manufacturing customers and could deploy internal mixing technology rather than purchasing LEON's equipment.
• Lonza Capsules & Health Ingredients: Lonza is a global CDMO with substantial LNP and nanoparticle formulation capabilities as part of its broader biologics manufacturing offering. While not a direct equipment competitor, it competes for the same pharma customer wallet for nanoparticle manufacturing services and could be both a partner and competitor to LEON's platform.

Emerging players

• CordenPharma: CordenPharma is a CDMO with growing capabilities in lipid nanoparticle formulation and complex injectable manufacturing. Competes for advanced therapeutics manufacturing contracts from pharma/biotech customers in LEON's target segments.

Direct peers

• Knauer Wissenschaftliche Geräte: Knauer supplies HPLC and mixing/impregnation equipment used in pharmaceutical formulation and process development, including for nanoparticle applications. Competes with LEON in the pharma equipment space, particularly for GMP-compliant process development systems.
• Cytiva (formerly Precision NanoSystems): Cytiva acquired Precision NanoSystems, the most direct competitor to LEON in LNP/nanoparticle manufacturing equipment (e.g., NanoAssemblr platform). Competes head-to-head with FR-JET® in the same pharma/biotech/CDMO customer base for scalable LNP and nanoparticle production.
• Microfluidics International (IDEX): Microfluidics International, part of IDEX Corporation, manufactures high-shear microfluidic homogenizers used in pharmaceutical nanoparticle production. Directly competes with LEON's FR-JET® impingement technology for lipid nanoparticle and nano-emulsion manufacturing applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/LeonNanodrugs
• Facebookfacebook.com/168226103926561
• LinkedInlinkedin.com/company/leon-nanodrugs

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about leon nanodrugs